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Simultaneous occurrences of
T-cell and B-cell neoplasms are
rare, and etiological relationships
between these two malignancies
are poorly understood. We report
the case of a 76-year-old man
who presented with hypercalcemia,
multiple skin nodular lesions, fati-
gue, episodic fever, and night
sweats. PET/CT scan showed dif-
fuse skin and subcutaneous fat
plane active lesions, supra- and
infra- diaphragmatic active lymph
nodes, liver and spleen involve-
ment, bone marrow inﬁltration,
and nonspeciﬁc bilateral lung nod-
ules. A skin biopsy showed a high
grade CD30-positive/ALK-nega-
tive T-cell lymphoma. A bone
marrow biopsy showed involve-
ment by the same neoplastic cells.
Additionally, a monoclonal lambda
restricted plasma cell population
(15% of marrow elements) was
identiﬁed, which, in view of an
IgA lambda spike in the serum,
was consistent with plasma cell
myeloma. To the best of our
knowledge, this case is the ﬁrst
reported case of a plasma cell neo-
plasm associated with an aggressive
CD30-positive ALK-negative sys-
temic T-cell lymphoma with skin
involvement. Reporting such cases
is important as it adds to the pool
of rare cases of concomitant T-cell
neoplasms and plasma cell myelo-
mas, and might help in determin-
ing an etiological relationship, if
any, between these two hematolog-
ical malignancies.
Simultaneous occurrences of
T-cell and B-cell lymphoprolifera-
tive disorders have rarely beendescribed.1 Of note, several cases
of T-cell lymphomas, including
primary cutaneous lymphomas in
association with clonal plasma cell
proliferations, have been reported
with variable clinical presenta-
tion.1–3 However, the relationship
between these two neoplasms
remains poorly understood.
A 76-year-old man with
known chronic renal insufﬁciency
presented with a one month his-
tory of multiple diffuse skin nod-
ules. At presentation, he was
found to have anemia (hemoglo-
bin: 10.9 g/dL) and hypercalcemia
(serum calcium: 11.1 mg/dL).
Serum protein electrophoresis
and immunoﬁxation revealed an
IgA lambda spike (9.6 g/L). On
physical examination, the patient
had multiple cutaneous skin-col-
ored to erythematous papules
and nodules, involving his bilat-
eral lower and upper extremities
and trunk (Figure 1A and B). A
PET/CT scan showed multiple
diffuse active lesions in the skin,
subcutaneous tissue, lung, liver,
spleen, and bone marrow, and
multiple active lymph nodes. A
skin biopsy showed a superﬁcial
and deep dermal inﬁltrate sparing
the epidermis, consisting of med-
ium to large-sized atypical cells
with irregular nuclei, occasionally
prominent nucleoli, variable chro-
matin pattern, and high mitotic
activity (Figure 1C and D). No
anaplastic-looking cells were seen.
The atypical cells were positive
for CD45, CD3, CD30 (strong
and diffuse), CD43, and negative
for ALK, CD4, CD5, CD7,
CD8, CD10, CD20, CD34,
CD56, TdT, PAX-5, myeloper-
oxidase, BCL-6, PD-1, and
in situ hybridization for EBV-
encoded RNA (Figure 1E and
F). Ki-67 proliferation index was
around 90%. The bone marrowHembiopsy showed involvement by
similar atypical cells (Figure 1G
and H), with marked (3+)
increase in reticulin ﬁbrosis (not
shown). Furthermore, there was
an increase in CD138-positive
lambda light chain-restricted
plasma cells (Figure 1H–J),
accounting for around 15% of
marrow elements. The overall
ﬁndings were consistent with an
aggressive CD30-positive T-cell
neoplasm involving multiple
organs with a concomitant IgA
lambda-secreting plasma cell mye-
loma. Unfortunately, shortly after
the diagnosis was made, the
patient’s condition rapidly deterio-
rated, leading to his demise.
According to the World
Health Organization (WHO)
classiﬁcation of tumors of hemato-
poietic and lymphoid tissues, the
main differential diagnoses in this
case include ALK-negative ana-
plastic large cell lymphoma
(ALCL) and CD30-positive
peripheral T-cell lymphoma, not
otherwise speciﬁed (PTCL,
NOS).4 We followed the WHO
conservative approach where
ALK-negative ALCL should be
diagnosed only in cases where the
morphology and the immunophe-
notype are very similar to those
of the ALK-positive cases.4 We
believed that the overall clinical
and histologic ﬁndings were more
consistent with a PTCL, NOS
than an ALCL or a primary cuta-
neous T-cell lymphoma. Interest-
ingly, there was a concomitant
plasma cell myeloma (PM) in the
bone marrow. The relationship
between T-cell neoplasms and
PM is unclear, as various studies
have described different possible
mechanisms for tumorigene-
sis.2,3,5,6 Therefore, the chronolog-
ical sequence of tumors could not
be determined with certainty.atol Oncol Stem Cell Ther 8(1) First Quarter 2015
Figure 1. Right lower extremity (A) and left upper extremity (B) skin lesions. Superficial and deep infiltrate dermal infiltrate (H&E, 40·) (C), consisting of medium to large-
sized atypical cells with irregular nuclei, occasionally prominent nucleoli, variable chromatin pattern, and a high mitotic activity, sparing the epidermis (H&E, 400·) (D).
Diffuse positivity for CD3 (E) and CD30 (F) in the atypical infiltrate, with no expression of CD5 or ALK (not shown). Hypercellular bone marrow diffusely involved by an atypical
cell population (H&E, 40·) (G), morphologically similar to the infiltrate in the skin, admixed with clusters of plasma cells (H&E, 400·) (H). Increased plasma cells highlighted
by CD138 (I) showing lambda light chain restriction (J), and negative for kappa light chains (not shown).
letter to editorIn summary, this case is of
value because, to the best of our
knowledge, it is the ﬁrst reported
case of a plasma cell neoplasm
associated with an aggressiveHematol Oncol Stem Cell Ther 8(1) First Quarter 2015CD30-positive PTCL, NOS.
Reporting such cases is important
as it adds to the pool of rare cases
of concomitant T-cell neoplasms
and plasma cell myelomas, andmight help in determining an
etiological relationship, if any,
between these two hematological
malignancies.41
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